During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

The recommendation is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd), for the ...

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

This delay allowed the cancer to progress again and was an extremely worrying time for Thomas and his family. A fourth line ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

New techniques include a pellet made of coral and a hydrogel that can be pressed around the bone to help eliminate pain.

Headquartered in Vaughan, Ontario with several branches in Southeast Asia, Cell Biotechnology Co., Ltd. specializes in advanced stem cell transplantation technology. With a focus on improving patient ...

Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL) that develops from B-lymphocytes and is generally slow-growing or ...